Published: 12 October 2026 | 6.00 AM
Last Updated: 12 October 2026 | 6.30 AM
Sahajanand Medical Technologies IPO Review: Improving Profits, Premium Valuation
IPO Snapshot
| Particulars | Details |
|---|---|
| Chanakya View | 🟡 Selective Apply |
| Overall Rating | ⭐⭐⭐☆☆ — 3/5 |
| GMP Today | Rs. 40 – Updated frequently |
| Issue Size | Rs. 475.48 crore |
| Price Band | Rs. 327–344 |
| Lot Size | 43 shares |
| Minimum Retail Investment | Rs. 14,792 |
| IPO Opens | October 15, 2026 |
| IPO Closes | October 19, 2026 |
| Allotment | October 21, 2026, tentative |
| Listing | October 23, 2026, tentative |
| Exchange | BSE, NSE |
| Issue Structure | Entirely Offer for Sale |
| Registrar | MUFG Intime India Pvt. Ltd. |
Investor Decision Box
| Question | Chanakya View |
|---|---|
| Suitable for Listing Gain? | Conditional on demand and valuation |
| Suitable for Long-Term? | Selective; monitor earnings sustainability |
| Risk Level | High |
| Business Quality | ⭐⭐⭐⭐☆ |
| Financial Strength | ⭐⭐⭐☆☆ |
| Balance Sheet | ⭐⭐⭐☆☆ |
👉 | IPO GMP|IPO Reviews |IPO Subscription|IPO Allotment
Chanakya View
Sahajanand Medical Technologies offers exposure to specialised cardiovascular devices through coronary stents, heart valves and occluders. Its international footprint, research capabilities and improving profitability support the investment case.
However, at Rs. 344 and supplied FY26 EPS of Rs. 6.80, the indicative P/E is approximately 50.6 times, leaving limited room for earnings disappointment. The supplied alternative EPS of Rs. 5.94 implies approximately 57.9 times earnings; its calculation basis requires clarification. An OFS does not itself dilute outstanding shares.
Borrowings have increased, while the June quarter’s PAT margin was below FY26. Investors should assess cash generation and profitability alongside revenue growth.
Chanakya Recommendation: 🟡 Selective Apply,
About the Company
Founded in 2001 by Dhirajlal Kotadia, Sahajanand Medical Technologies develops medical devices for vascular and structural heart interventions. Major brands include Supraflex Cruz, Hydra and Cocoon.
The Company’s products reach more than 76 countries. Two research centres in India and Thailand support product development, backed by 102 professionals, 102 granted patents and 71 pending applications. Distribution combines direct operations, hospital relationships and overseas distributors.
Why This IPO Stands Out
- Specialised portfolio covering stents, balloons, heart valves and occluders.
- International presence provides access to multiple healthcare markets.
- Clinical studies and intellectual property support product differentiation.
- FY26 profitability improved substantially after the FY24 loss.
Key Risks
- Premium valuation demands sustained earnings delivery.
- Regulatory approvals, clinical outcomes and product quality are critical.
- Borrowings increased further during the June quarter.
- The company receives no proceeds because the issue is entirely OFS.
- International operations create currency and market-access exposure.
Financial Snapshot — Rs. Crore
| Particulars | FY26 | FY25 | FY24 |
|---|---|---|---|
| Total Income | 1,218.73 | 1,035.96 | 908.59 |
| EBITDA | 170.66 | 128.02 | 110.05 |
| PAT | 69.08 | 25.15 | −7.35 |
| Borrowings | 269.53 | 224.96 | 175.27 |
Chanakya Interpretation: Total income increased approximately 17.6%, while PAT rose 174.7% in FY26. June-quarter income reached Rs. 354.33 crore, with PAT of Rs. 15.09 crore. Borrowings climbed to Rs. 320.63 crore. Improving earnings are encouraging, but debt growth and modest net margins warrant attention. Business Quality Score
| Parameter | Editorial Rating |
|---|---|
| Business Model | ⭐⭐⭐⭐☆ |
| Industry Outlook | ⭐⭐⭐⭐☆ |
| Financial Performance | ⭐⭐⭐☆☆ |
| Research Capabilities | ⭐⭐⭐⭐☆ |
| Balance Sheet | ⭐⭐⭐☆☆ |
| Valuation Comfort | ⭐⭐☆☆☆ |
Company Address
Sahajanand Estate, Wakharia Wadi, near Dabholi Char Rasta, Nani Ved, Ved Road, Surat, Gujarat–395004.
Lead Managers
Motilal Oswal Investment Advisors, Avendus Capital, HSBC Securities & Capital Markets (India), and Nuvama Wealth Management.
IPO Proceeds and Why They Matter
The Rs. 475.48 crore issue is entirely an Offer for Sale. Proceeds go to selling shareholders; Sahajanand receives no funds for expansion, debt repayment or working capital. Future growth must therefore rely on internal cash generation and other financing sources.
Business Outlook
Demand for cardiovascular interventions offers growth opportunities for Sahajanand’s stents, valves and occluders. Its international distribution network and research capabilities provide a platform for expansion. Converting clinical acceptance into profitable sales, maintaining regulatory approvals and controlling costs will determine future performance.
Strengths vs Concerns
| Strengths | Concerns |
|---|---|
| Specialised cardiovascular portfolio | Premium earnings valuation |
| International distribution | Regulatory and quality risks |
| Research and patent base | Rising borrowings |
| Improving annual profitability | Modest net margins |
Who Should Apply?
| Investor Type | Suitability |
|---|---|
| Listing-gain investors | Conditional on subscription quality |
| Long-term investors | Selective |
| Conservative investors | Limited suitability |
| Investors accepting higher risk | Consider after valuation review |
Chanakya Final Verdict
Sahajanand combines specialised products, international reach and improving earnings. However, the indicative FY26 P/E of approximately 50.6 times at the upper band demands sustained execution. Rising borrowings and modest profitability reduce valuation comfort. The alternative supplied EPS needs reconciliation before relying on another P/E estimate. Chanakya Recommendation: 🟡 Selective Apply. Long-term investors should assess cash generation, regulatory disclosures and earnings consistency. Listing-gain applicants should monitor subscription demand; GMP alone cannot establish investment merit or guarantee returns.
Frequently Asked Questions
How will Sahajanand Medical Technologies use IPO proceeds?
The company receives no proceeds because the issue consists entirely of shareholder sales.
Does Sahajanand Medical Technologies IPO dilute shares?
The supplied share count remains unchanged because no fresh shares are issued.
Should investors apply for Sahajanand Medical Technologies IPO?
Selective consideration is appropriate, subject to valuation clarification and risk tolerance.
Summary
A differentiated medical-device business, but valuation and borrowing trends warrant careful scrutiny.